Literature DB >> 6846250

A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.

J Rubin, S Sorensen, A J Schutt, G A van Hazel, M J O'Connell, C G Moertel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6846250     DOI： 10.1097/00000421-198306000-00012

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN： 0277-3732            Impact factor:   2.339


× No keyword cloud information.
  8 in total

1.  Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.

Authors:  Lukáš Tenora; Jesse Alt; Ranjeet P Dash; Alexandra J Gadiano; Kateřina Novotná; Vijayabhaskar Veeravalli; Jenny Lam; Quinn R Kirkpatrick; Kathryn M Lemberg; Pavel Majer; Rana Rais; Barbara S Slusher
Journal:  J Med Chem       Date:  2019-03-29       Impact factor: 7.446

2.  Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.

Authors:  Jesse Alt; Michelle C Potter; Camilo Rojas; Barbara S Slusher
Journal:  Anal Biochem       Date:  2015-01-10       Impact factor: 3.365

Review 3.  Targeting Energy Metabolism in Cancer Treatment.

Authors:  Joanna Kubik; Ewelina Humeniuk; Grzegorz Adamczuk; Barbara Madej-Czerwonka; Agnieszka Korga-Plewko
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

4.  Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON).

Authors:  A Rahman; F P Smith; P T Luc; P V Woolley
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 5.  Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.

Authors:  Diana Cervantes-Madrid; Yair Romero; Alfonso Dueñas-González
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

Review 6.  Advancing Cancer Treatment by Targeting Glutamine Metabolism-A Roadmap.

Authors:  Anna Halama; Karsten Suhre
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

Review 7.  We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Authors:  Kathryn M Lemberg; James J Vornov; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.009

8.  mTOR-S6K1 pathway mediates cytoophidium assembly.

Authors:  Zhe Sun; Ji-Long Liu
Journal:  J Genet Genomics       Date:  2019-01-31       Impact factor: 4.275
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.